Research programme: cancer therapeutics - BioLineRx

Drug Profile

Research programme: cancer therapeutics - BioLineRx

Alternative Names: BL-2010; BL-2030; BL-3040; BL-4050; BL-5020; BL-M010; EDP 08; EDP 17; EDP 19; EDP 20; EDP 23; EDP 24; EDP-33

Latest Information Update: 08 Jan 2013

Price : $50

At a glance

  • Originator BioLineRx
  • Class Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 08 Jan 2013 Early research is ongoing in Israel
  • 19 Mar 2009 Early research is ongoing in Israel
  • 20 Dec 2007 Pharmacodynamics data from a preclinical study in prostate cancer released by BioLineRx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top